Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | RAF1 | P04049 | 2/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403001 | 0.97 | KMT2A (0.51) | KMT2APOLBRAF1MAP2K1PPARA | |
| SCHEMBL5397939 | 0.94 | KMT2A (0.58) | KMT2APOLBRAF1MAP2K1PPARA | |
| SCHEMBL5399251 | 0.93 | POLB (0.46) | KMT2APOLBPPARAAPPLMNA | |
| SCHEMBL5397971 | 0.91 | KMT2A (0.48) | KMT2APOLBPPARAAPPPDE10A | |
| SCHEMBL5405645 | 0.91 | SMN1; SMN2 (0.51) | KMT2APPARAAPPPDE10ALMNA | |
| SCHEMBL4931927 | 0.91 | LMNA (0.45) | RAF1MAP2K1PPARAAPPLMNA | |
| SCHEMBL5403428 | 0.90 | APP (0.49) | PPARAAPPNPC1LMNAHPGD | |
| SCHEMBL5402571 | 0.90 | POLB (0.46) | KMT2APOLBPPARALMNAHPGD | |
| SCHEMBL5394185 | 0.89 | KMT2A (0.51) | KMT2APPARAAPPMEN1LMNA | |
| SCHEMBL4929491 | 0.88 | APEX1 (0.46) | RAF1MAP2K1APPPDE10ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | KMT2A 2451/4885POLB 527/4885RAF1 1038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.